|
New Bayer U.S. Innovation Center starts its operations
|
12 January 2011 |
|
Bayer: 35 million Euros for the expansion of the development of biologicals
|
13 December 2010 |
|
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies with VEGF Trap-Eye
|
23 November 2010 |
|
Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
|
15 November 2010 |
|
Bayer raises its brand profile
|
08 November 2010 |
|
Phase III ROCKET AF Study of Rivaroxaban meets its primary efficacy endpoint with Comparable Safety vs. Warfarin
|
02 November 2010 |
|
Bayer lifts sales and earnings again
|
29 October 2010 |
|
21-Year Long-term Follow-up Study Demonstrates Significant Survival Advantage with Betaferon Treatment
|
18 October 2010 |
|
Bayer's Xarelto® Recognised with 2010 International Prix Galien Award
|
07 October 2010 |
|
Bayer's Rivaroxaban Successfully Meets Primary Efficacy Outcome
|
01 September 2010 |
|
Bayer increases sales and earnings in the second quarter
|
30 July 2010 |
|
Bayer Schering Pharma enters strategic partnership with Hospital in China
|
19 July 2010 |
|
Bayer Schering Pharma and OncoMed Pharmaceuticals Enter Strategic Alliance
|
18 June 2010 |
|
Trial of Nexavar® in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint
|
14 June 2010 |
|
Bayer Schering Pharma Enhances U.S. Research Strategy with New Innovation Center
|
18 May 2010 |
|
Bayer receives approval for its new oral contraceptive in the U.S.
|
17 May 2010 |
|
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib
|
10 May 2010 |
|
Bayer Schering Pharma Initiates Phase III Trial of Regorafenib (BAY 73-4506)
|
10 May 2010 |
|
Bayer Schering Pharma and EndoCeutics Enter into a Global Agreement
|
06 May 2010 |
|
Bayer achieves strong gains in sales and earnings
|
30 April 2010 |